Civitas Therapeutics Obtains $20,000,000 Series A Funding

  • Feed Type
  • Date
    1/10/2011
  • Company Name
    Civitas Therapeutics
  • Mailing Address
    190 Everett Ave. Chelsea, MA 02150
  • Company Description
    Civitas is a privately held pharmaceutical company focused on developing products with a clinically proven dry powder pulmonary delivery platform. The proprietary dry powder and device combination is unique in its ability to deliver a large, precise dose independent of inspiratory flow rate from a simple, passive device.
  • Website
    http://www.civitastherapeutics.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $20,000,000
  • Transaction Round
    Series A
  • Proceeds Purposes
    The proceeds of the financing will be primarily used to advance Civitas’ lead program for treating patients with Parkinson’s disease through clinical proof-of-concept. The company is a spin-out of Alkermes, Inc.’s pulmonary delivery business that includes the related technology, pipeline assets and the commercial ready manufacturing facility.
  • M&A Terms
  • Venture Investor
    Longitude Capital Management
  • Venture Investor
    Canaan Partners

Trending on Xconomy